Back

Thermally activated antibiotic production by probiotic bacteria for pathogen elimination

Dey, S.; Seyfert, C. E.; Fink-Straube, C.; Kany, A. M.; Mueller, R.; Sankaran, S.

2024-02-15 bioengineering
10.1101/2024.02.13.579303 bioRxiv
Show abstract

Peptide drugs have seen rapid advancement in biopharmaceutical development, with over 80 candidates approved globally. Despite their therapeutic potential, the clinical translation of peptide drugs is hampered by challenges in production yields and stability. Engineered bacterial therapeutics is a unique approach being explored to overcome these issues by using bacteria to produce and deliver therapeutic compounds at the body site of use. A key advantage of this technology is the possibility to control drug delivery within the body in real time using genetic switches. However, the performance of such genetic switches suffers when used to control drugs that require post-translational modifications or are toxic to the host. In this study, these challenges were experienced when attempting to establish a thermal switch for the production of a ribosomally synthesized and post-translationally modified peptide antibiotic, darobactin, in probiotic E. coli. These challenges were overcome by developing a thermo-amplifier circuit that combined the thermal-switch with a T7 RNA Polymerase and its promoter that overcame limitations imposed by the host transcriptional machinery due to its orthogonality to it. This circuit enabled production of pathogen-inhibitory levels of darobactin at 40{degrees}C while maintaining leakiness below the detection limit at 37{degrees}C. More impressively, the thermo-amplifier circuit sustained production beyond the thermal induction duration. Thus, raised temperature for 2 h was sufficient for the bacteria to produce pathogen-inhibitory levels of darobactin even in the physiologically relevant simulated conditions of the intestines that include bile salts and low nutrient levels. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=138 SRC="FIGDIR/small/579303v2_ufig1.gif" ALT="Figure 1"> View larger version (21K): org.highwire.dtl.DTLVardef@1cdb311org.highwire.dtl.DTLVardef@1a7523aorg.highwire.dtl.DTLVardef@77b68org.highwire.dtl.DTLVardef@136f52b_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Microbial Cell Factories
27 papers in training set
Top 0.1%
30.7%
2
Applied and Environmental Microbiology
339 papers in training set
Top 0.7%
9.7%
3
Microbial Biotechnology
34 papers in training set
Top 0.1%
8.8%
4
ACS Synthetic Biology
287 papers in training set
Top 0.4%
8.8%
50% of probability mass above
5
New Biotechnology
12 papers in training set
Top 0.1%
5.4%
6
PLOS ONE
5266 papers in training set
Top 40%
2.7%
7
Frontiers in Microbiology
427 papers in training set
Top 4%
2.4%
8
International Journal of Biological Macromolecules
76 papers in training set
Top 1%
1.7%
9
Scientific Reports
3612 papers in training set
Top 57%
1.7%
10
Frontiers in Bioengineering and Biotechnology
98 papers in training set
Top 1%
1.7%
11
Biotechnology for Biofuels
14 papers in training set
Top 0.2%
1.5%
12
Nucleic Acids Research
1281 papers in training set
Top 10%
1.5%
13
International Journal of Molecular Sciences
494 papers in training set
Top 9%
1.4%
14
Biotechnology and Bioengineering
53 papers in training set
Top 0.7%
1.1%
15
Nature Communications
5641 papers in training set
Top 51%
1.1%
16
The FEBS Journal
93 papers in training set
Top 1%
1.1%
17
Synthetic and Systems Biotechnology
11 papers in training set
Top 0.1%
1.1%
18
Advanced Science
286 papers in training set
Top 7%
1.1%
19
Biotechnology Journal
11 papers in training set
Top 0.2%
1.1%
20
Metabolic Engineering
75 papers in training set
Top 0.6%
1.1%
21
Journal of Biotechnology
11 papers in training set
Top 0.2%
1.0%
22
Biomedicine & Pharmacotherapy
42 papers in training set
Top 1%
0.8%
23
Trends in Biotechnology
12 papers in training set
Top 0.3%
0.8%
24
Applied Microbiology and Biotechnology
32 papers in training set
Top 1%
0.6%